In patients older than 40 years, the type 2 diabetes drug class showed increased benefits over DPP-4 inhibitors at reducing the risk for dementia and Alzheimer’s disease.
Medscape Medical News
SGLT-2 Inhibitors Reduce Dementia Risk vs DPP-4 Inhibitors
